Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Xenetic Biosciences's share price for the quarter that ended in Mar. 2024 was $3.77. Xenetic Biosciences's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 1.54 Mil. Therefore, Xenetic Biosciences's market cap for the quarter that ended in Mar. 2024 was $5.81 Mil.
Xenetic Biosciences's quarterly market cap
declined
from Sep. 2023 ($7.51 Mil) to Dec. 2023 ($5.32 Mil) but then
increased
from Dec. 2023 ($5.32 Mil) to Mar. 2024 ($5.81 Mil).
Xenetic Biosciences's annual market cap
declined
from Dec. 2021 ($17.34 Mil) to Dec. 2022 ($4.32 Mil) but then
increased
from Dec. 2022 ($4.32 Mil) to Dec. 2023 ($5.32 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Xenetic Biosciences's Enterprise Value for Today is $-1.80 Mil.
Xenetic Biosciences Market Cap Historical Data
The historical data trend for Xenetic Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Xenetic Biosciences's Market Cap
For the Biotechnology subindustry, Xenetic Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenetic Biosciences's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Xenetic Biosciences's Market Cap falls into.
Xenetic Biosciences Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Xenetic Biosciences's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenetic Biosciences (NAS:XBIO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Xenetic Biosciences Market Cap Related Terms
Thank you for viewing the detailed overview of Xenetic Biosciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Xenetic Biosciences (Xenetic Biosciences) Business Description
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XBIO has been successfully added to your 